Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders

Research output: Contribution to journalReview articlepeer-review

Abstract

The mammalian target of rapamycin (mTOR) pathway is an highly conserved signal transduction axis involved in many cellular processes, such as cell growth, survival, transcription, translation, apoptosis, metabolism, motility and autophagy. Recently, this signalling pathway has come to the attention of the scientific community owing to the unexpected finding that inhibition of mTOR by rapamycin, an antibiotic with immunosuppressant and chemotherapeutic properties, extends lifespan in diverse animal models. Moreover, rapamycin has been reported to rescue the cellular phenotype in a progeroid syndrome [Hutchinson–Gilford Progeria syndrome (HGPS)] that recapitulates most of the traits of physiological ageing. The promising perspectives raised by these results warrant a better understanding of mTOR signalling and the potential applications of mTOR inhibitors to counteract ageing-associated diseases and increase longevity. This review is focused on these issues.

Original languageEnglish
Pages (from-to)1229-1244
Number of pages16
JournalBritish Journal of Clinical Pharmacology
DOIs
Publication statusPublished - Nov 1 2016

Keywords

  • ageing
  • Hutchinson–Gilford Progeria syndrome (HGPS)
  • lamin A
  • mTOR inhibitors
  • progeria-related diseases
  • rapamycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders'. Together they form a unique fingerprint.

Cite this